Neurological Surgery 脳神経外科50巻1号

2022年01月発行

特集 Precision Medicine—個別化医療を目指した遺伝子診断と新治療の知見 Ⅰ悪性脳腫瘍

Diffuse midline glioma

著者： 齋藤竜太¹

所属機関： ¹名古屋大学大学院医学系研究科脳神経外科学分野

ページ範囲：P.29 - P.38

Point
・Diffuse midline glioma（DMG），H3 K27M-mutantは，正中付近に存在する浸潤性の高悪性度星状膠腫でH3F3AもしくはHIST1H3B/CにK27M変異（H3 K27M変異）を有する腫瘍と定義される．
・脳幹部神経膠腫，視床神経膠腫，脊髄神経膠腫が代表であるが，一般に予後不良な腫瘍とされる．
・近年，H3 K27M変異を含む多くの遺伝子異常が同定されており，個別化医療への期待が高まっている．

参考文献

1）Hawkins C, et al：Diffuse midline glioma, H3 K27M-mutant. Louis DN, et al（eds）：WHO Classification of tumours of the Central Nervous System. IARC, Lyon, 2016, pp. 57-59

2）武笠晃丈：脳腫瘍におけるヒストンH3 K27M変異の意義．Neuro-Oncol進歩 24：7-17, 2017

3）Schwartzentruber J, et al：Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482：226-231, 2012

4）Gessi M, et al：Evidence of H3 K27M mutations in posterior fossa ependymomas. Acta Neuropathol 132：635-637, 2016

5）Pagès M, et al：Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade Ⅰ ganglioglioma. Brain Pathol 28：103-111, 2018

6）Bender S, et al：Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell 24：660-672, 2013

7）Chan KM, et al：The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev 27：985-990, 2013

8）Lewis PW, et al：Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 340：857-861, 2013

9）Zhang L, et al：Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. Nat Genet 46：726-730, 2014

10）Buczkowicz P, et al：Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet 46：451-456, 2014

11）Maeda S, et al：H3F3A mutant allele specific imbalance in an aggressive subtype of diffuse midline glioma, H3 K27M-mutant. Acta Neuropathol Commun 8：8, 2020

12）Srikanthan D, et al：Diffuse intrinsic pontine glioma：current insights and future directions. Chin Neurosurg J 7：6, 2021

13）Truffaux N, et al：Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma. Neuro Oncol 17：953-964, 2015

14）Geoerger B, et al；ITCC（Innovative Therapies for Children with Cancer）European Consortium：Innovative Therapies for Children with Cancer pediatric phase Ⅰ study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol 13：109-118, 2011

15）Chornenkyy Y, et al：Poly-ADP-ribose polymerase as a therapeutic target in pediatric diffuse intrinsic pontine glioma and pediatric high-grade astrocytoma. Mol Cancer Ther 14：2560-2568, 2015

16）Warren KE, et al：Genomic aberrations in pediatric diffuse intrinsic pontine gliomas. Neuro Oncol 14：326-332, 2012

17）Grasso CS, et al：Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med 21：555-559, 2015

18）Hashizume R, et al：Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med 20：1394-1396, 2014

19）Wiese M, et al：No significant cytotoxic effect of the EZH2 inhibitor tazemetostat（EPZ-6438）on pediatric glioma cells with wildtype histone 3 or mutated histone 3.3. Klin Padiatr 228：113-117, 2016

20）Veringa SJ, et al：In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma. PLoS One 8：e61512, 2013

21）Prabhu VV, et al：Dopamine receptor D5 is a modulator of tumor response to dopamine receptor D2 antagonism. Clin Cancer Res 25：2305-2313, 2019

22）Arrillaga-Romany I, et al：Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. Neuro Oncol 22：94-102, 2020

23）Arrillaga-Romany I, et al：A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget 8：79298-79304, 2017

24）Stein MN, et al：First-in-human clinical trial of oral ONC201 in patients with refractory solid tumors. Clin Cancer Res 23：4163-4169, 2017

25）Stein MN, et al：Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration. J Immunother Cancer 7：136, 2019

26）Himes BT, et al：Treatment strategies in diffuse midline gliomas with the H3K27M mutation：the role of convection-enhanced delivery in overcoming anatomic challenges. Front Oncol 9：31, 2019

27）Saito R, et al：Phase Ⅰ trial of convection-enhanced delivery of nimustine hydrochloride（ACNU）for brainstem recurrent glioma. Neurooncol Adv 2：vdaa033, 2020

28）Souweidane MM, et al：Convection-enhanced delivery for diffuse intrinsic pontine glioma：a single-centre, dose-escalation, phase 1 trial. Lancet Oncol 19：1040-1050, 2018

29）Vanan MI, Eisenstat DD：DIPG in children - what can we learn from the past? Front Oncol 5：237, 2015

30）Albright AL, et al：Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas：a report from the Children's Cancer Group. Neurosurgery 33：1026-1029；discussion 1029-1030, 1993

31）Cage TA, et al：Feasibility, safety, and indications for surgical biopsy of intrinsic brainstem tumors in children. Childs Nerv Syst 29：1313-1319, 2013

32）Frappaz D, et al：Preradiation chemotherapy may improve survival in pediatric diffuse intrinsic brainstem gliomas：final results of BSG 98 prospective trial. Neuro Oncol 10：599-607, 2008

33）Aihara K, et al：H3F3A K27M mutations in thalamic gliomas from young adult patients. Neuro Oncol 16：140-146, 2014

34）Osada Y, et al：H3K27M and TERT promoter mutations are poor prognostic factors in surgical cases of adult thalamic high-grade glioma. Neurooncol Adv 3：vdab038, 2021

35）Kikuchi Z, et al：TERT promoter mutation associated with multifocal phenotype and poor prognosis in patients with IDH wild-type glioblastoma. Neurooncol Adv 2：vdaa114, 2020

36）Ishi Y, et al：Prognostic role of H3K27M mutation, histone H3K27 methylation status, and EZH2 expression in diffuse spinal cord gliomas. Brain Tumor Pathol 37：81-88, 2020